Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434084 | 1.00 | GRM5 (0.63) | GRM5CYP1A2CYP2D6NPC1RAB9A | |
| SCHEMBL15049682 | 0.77 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL5653485 | 0.76 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL16289829 | 0.75 | GRM5 (0.61) | GRM5CYP1A2CYP2D6NPC1RAB9A | |
| SCHEMBL4150883 | 0.75 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4711039 | 0.74 | GRM5 (0.61) | GRM5CYP1A2CYP2D6NPC1RAB9A | |
| SCHEMBL4151041 | 0.74 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL1243386 | 0.73 | GRM5 (0.56) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4456131 | 0.73 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL23075939 | 0.72 | GRM5 (0.62) | GRM5CYP1A2CYP2D6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-20240285637-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution of the Advancement of Learning/McGill University (CA) | 2024-08-29 | — | — | US | claimed |
| CN-112257268-B | Reliability analysis method for hydraulic multi-way valve | 南京工业大学 | 2024-05-24 | — | — | CN | claimed |
| EP-4366739-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-05-15 | — | — | EP | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| CN-113418544-B | Automatic calibration method for initial position of encoder based on QEP | 重庆渝凌晶科智能控制技术研究院有限公司 | 2024-03-08 | — | — | CN | claimed |
| WO-2023125112-A1 | ANTAGONIST COMPOSITION AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATMENT OF SLEEP DISORDERS WITH CO-MORBID PSYCHIATRIC DISORDERS | 中国科学院深圳先进技术研究院 | 2023-07-06 | — | — | WO | claimed |
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | claimed |
| WO-2023279193-A2 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-01-12 | — | — | WO | claimed |
| CN-114225039-A | Antagonist composition and application thereof in preparation of medicine for treating sleep disorder and mental disease | 中国科学院深圳先进技术研究院 | 2022-03-25 | — | — | CN | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | disclosed |
| US-20260086067-A1 | System for the Simultaneous Monitoring of Constituents of an Electroplating Bath | TECHNIC, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3661500-B1 | USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE | NOVARTIS AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-3661501-B1 | USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE | NOVARTIS AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-3371163-B1 | PYRROLIDINE DERIVATIVES | HUA MEDICINE SHANGHAI LTD (CN) | 2022-03-30 | — | — | EP | disclosed |
| CN-114225039-A | Antagonist composition and application thereof in preparation of medicine for treating sleep disorder and mental disease | 中国科学院深圳先进技术研究院 | 2022-03-25 | — | — | CN | disclosed |
| CN-114144436-A | anti-mGluR 5 antibodies and uses thereof | H.隆德贝克有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | GRM5 319/4885CYP1A2 2019/4885CYP2D6 943/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GRM5 1/4885CYP1A2 4061/4885CYP2D6 3131/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRM5 1785/4885CYP1A2 3771/4885CYP2D6 4391/4885 |
| US-20260086067-A1 | System for the Simultaneous Monitoring of Constituents of an Electroplating Bath | FOS, NCS1, SCO2 | GRM5 3511/4885CYP1A2 1779/4885CYP2D6 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.